Overview
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-muta
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2027-11-30
2027-11-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study aims to assess the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and a PD-L1 expression < 1% regardless of STK11 mutation status (cohort A), or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Key Inclusion criteria- Histologically confirmed locally advanced (stage IIIb/IIIc not eligible for definitive
chemoradiation or surgical resection with curative intent) or metastatic (stage IV)
NSCLC without previous systemic treatment for metastatic disease. Prior (neo)adjuvant
treatment with chemotherapy and/or immunotherapy, or prior radiotherapy administered
sequentially or concomitantly with chemotherapy and/or immunotherapy for localized or
locally advanced disease are accepted if the time between therapy completion and
enrollment is > 12 months.
- Presence of a KRAS G12C mutation (all participants) and:
- Cohort A: PD-L1 expression < 1%, regardless of STK11 mutation status
- Cohort B: PD-L1 expression ≥ 1% and an STK11 co-mutation
- At least one measurable lesion per RECIST 1.1.
- ECOG performance status ≤ 1.
- Participants capable of swallowing study medication.
Key Exclusion criteria
- Participants whose tumors harbor an EGFR-sensitizing mutation and/or ALK rearrangement
by local laboratory testing. Participants with other known druggable alterations will
be excluded, if required by local guidelines
- Previous use of a KRAS G12C inhibitor or previous systemic treatment for metastatic
NSCLC.
- A medical condition that results in increased photosensitivity (i.e. solar urticaria,
lupus erythematosus, etc).
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Participants who are taking a prohibited medication (strong CYP3A inducers) that
cannot be discontinued at least seven days prior to the first dose of study treatment
and for the duration of the study
Other inclusion/exclusion criteria may apply